Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Emergency overcrowding and access block: A smaller problem than we think.

Innes GD, Sivilotti MLA, Ovens H, McLelland K, Dukelow A, Kwok E, Chopra A, Cheng I, Kalla D, Mackinnon D, Kim Sing C, Barclay N, Ross T, Chochinov A.

CJEM. 2019 Mar;21(2):177-185. doi: 10.1017/cem.2018.446. Epub 2018 Nov 8.

PMID:
30404680
2.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA.

JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.

PMID:
26181175
3.

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.

Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.

4.

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2015 Sep 1;137(5):1136-46. doi: 10.1002/ijc.29386. Epub 2014 Dec 18.

5.

Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.

Giannakeas V, Lubinski J, Gronwald J, Moller P, Armel S, Lynch HT, Foulkes WD, Kim-Sing C, Singer C, Neuhausen SL, Friedman E, Tung N, Senter L, Sun P, Narod SA.

Breast Cancer Res Treat. 2014 Aug;147(1):113-8. doi: 10.1007/s10549-014-3063-y. Epub 2014 Aug 1.

PMID:
25082516
6.

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21.

7.

A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.

Narod SA, Tung N, Lubinski J, Huzarski T, Robson M, Lynch HT, Neuhausen SL, Ghadirian P, Kim-Sing C, Sun P, Foulkes WD; Hereditary Breast Cancer Clinical Study Group.

Curr Oncol. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656.

8.

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.

J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.

9.

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.

Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA.

BMJ. 2014 Feb 11;348:g226. doi: 10.1136/bmj.g226.

10.

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.

Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, Neuhausen SL, Karlan B, Kim-Sing C, Huzarski T, Gronwald J, McCuaig J, Senter L, Tung N, Ghadirian P, Eisen A, Gilchrist D, Blum JL, Zakalik D, Pal T, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2014 Feb;143(3):579-86. doi: 10.1007/s10549-013-2823-4. Epub 2014 Jan 24.

PMID:
24458845
11.

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.

Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Llacuachaqui M, Chornokur G, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Br J Cancer. 2014 Jan 21;110(2):530-4. doi: 10.1038/bjc.2013.741. Epub 2013 Nov 28.

12.

Changing communication needs and preferences across the cancer care trajectory: insights from the patient perspective.

Thorne S, Hislop TG, Kim-Sing C, Oglov V, Oliffe JL, Stajduhar KI.

Support Care Cancer. 2014 Apr;22(4):1009-15. doi: 10.1007/s00520-013-2056-4. Epub 2013 Nov 28.

PMID:
24287506
13.

The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.

Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, Manoukian S, Zakalik D, Armel S, Senter L, Eng C, Grunfeld E, Chiarelli AM, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2013 Nov;142(1):177-85. doi: 10.1007/s10549-013-2729-1. Epub 2013 Oct 18.

14.

Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.

Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA.

J Clin Oncol. 2013 Nov 1;31(31):3914-9. doi: 10.1200/JCO.2012.47.7893. Epub 2013 Aug 26.

15.

Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.

Metcalfe KA, Kim-Sing C, Ghadirian P, Sun P, Narod SA.

Clin Genet. 2014 Jan;85(1):21-30. doi: 10.1111/cge.12233. Epub 2013 Aug 26.

PMID:
23859469
16.

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.

BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.

17.

International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.

Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, Lubinski J, Tung N, Eng C, Gilchrist D, Blum J, Neuhausen SL, Singer CF, Ghadirian P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Ann Surg Oncol. 2013 Nov;20(12):3817-22. doi: 10.1245/s10434-013-3040-4. Epub 2013 Jun 6.

18.

Of Guinea pigs and gratitude: the difficult discourse of clinical trials from the cancer patient perspective.

Thorne S, Taylor K, Stephens JM, Kim-Sing C, Hislop TG.

Eur J Cancer Care (Engl). 2013 Sep;22(5):663-72. doi: 10.1111/ecc.12075. Epub 2013 Jun 4.

PMID:
23731223
19.

The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Gynecol Oncol. 2013 Jul;130(1):127-31. doi: 10.1016/j.ygyno.2013.03.027. Epub 2013 Apr 3.

PMID:
23562522
20.

Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.

Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, Neuhausen SL, Kim-Sing C, Tung N, Karlan B, Foulkes WD, Sun P, Narod S; Hereditary Breast Cancer Study Group.

Fertil Steril. 2013 May;99(6):1724-8. doi: 10.1016/j.fertnstert.2013.01.109. Epub 2013 Feb 13.

PMID:
23414920
21.

Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?

Narod SA, Metcalfe K, Lynch HT, Ghadirian P, Robidoux A, Tung N, Gaughan E, Kim-Sing C, Olopade OI, Foulkes WD, Robson M, Offit K, Jakubowska A, Byrski T, Huzarski T, Sun P, Lubinski J.

Breast Cancer Res Treat. 2013 Feb;138(1):273-9. doi: 10.1007/s10549-013-2429-x. Epub 2013 Feb 6.

PMID:
23381743
22.

Poor communication in cancer care: patient perspectives on what it is and what to do about it.

Thorne S, Oliffe JL, Stajduhar KI, Oglov V, Kim-Sing C, Hislop TG.

Cancer Nurs. 2013 Nov-Dec;36(6):445-53. doi: 10.1097/NCC.0b013e31827eeda4.

PMID:
23348667
23.

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.

Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Friedman E, Llacuachaqui M, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Br J Cancer. 2012 Dec 4;107(12):2005-9. doi: 10.1038/bjc.2012.483. Epub 2012 Oct 25.

24.

Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, Gilchrist DM, Blum JL, Zakalik D, Singer C, Fallen T, Ginsburg O, Huzarski T, Sun P, Narod SA.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1089-96. doi: 10.1158/1055-9965.EPI-12-0201. Epub 2012 May 7.

25.

The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.

Tyldesley S, Peacock M, Morris JW, So A, Kim-Sing C, Quirt J, Carter M, Pickles T.

Can Urol Assoc J. 2012 Apr;6(2):89-94. doi: 10.5489/cuaj.11158.

26.

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, Ghadirian P, Neuhausen SL, Demsky R, Tung N, Ainsworth P, Senter L, Eisen A, Eng C, Singer C, Ginsburg O, Blum J, Huzarski T, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res. 2012 Mar 9;14(2):R42.

27.

Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers.

McGee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung N, Kim-Sing C, Karlan B, Foulkes WD, Ainsworth P, Ghadirian P, Senter L, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Obesity (Silver Spring). 2012 Jun;20(6):1288-92. doi: 10.1038/oby.2011.394. Epub 2012 Jan 19.

28.

The risk of breast cancer in women with a BRCA1 mutation from North America and Poland.

Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, Foulkes WD, Kilar E, Kim-Sing C, Neuhausen SL, Armel S, Gilchrist D, Sweet K, Gronwald J, Eisen A, Gorski B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2012 Jul 1;131(1):229-34. doi: 10.1002/ijc.26369. Epub 2011 Sep 22.

29.

Locally Advanced Cutaneous Squamous Cell Carcinoma: Two Case Reports of Dramatic Responses to Sequential Cisplatin, Docetaxel and Radiotherapy.

Dennis KE, Kim-Sing C, Laskin J.

World J Oncol. 2011 Aug;2(4):199-203. doi: 10.4021/wjon328w. Epub 2011 Aug 24.

30.

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA.

Br J Cancer. 2011 Apr 26;104(9):1384-92. doi: 10.1038/bjc.2011.120. Epub 2011 Apr 12.

31.

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini D, Sun P, Narod SA.

Breast Cancer Res Treat. 2011 May;127(1):287-96. doi: 10.1007/s10549-010-1336-7. Epub 2011 Jan 9.

PMID:
21221768
32.

Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Natl Cancer Inst. 2010 Dec 15;102(24):1874-8. doi: 10.1093/jnci/djq443. Epub 2010 Nov 23.

PMID:
21098759
33.

Patient perceptions of helpful communication in the context of advanced cancer.

Stajduhar KI, Thorne SE, McGuinness L, Kim-Sing C.

J Clin Nurs. 2010 Jul;19(13-14):2039-47. doi: 10.1111/j.1365-2702.2009.03158.x.

PMID:
20920030
34.

BRCA1 and BRCA2 families and the risk of skin cancer.

Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Fam Cancer. 2010 Dec;9(4):489-93. doi: 10.1007/s10689-010-9377-y.

PMID:
20809262
35.

Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy.

Howard AF, Bottorff JL, Balneaves LG, Kim-Sing C.

BMC Womens Health. 2010 Aug 5;10:24. doi: 10.1186/1472-6874-10-24.

36.

Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.

Dennis J, Ghadirian P, Little J, Lubinski J, Gronwald J, Kim-Sing C, Foulkes W, Moller P, Lynch HT, Neuhausen SL, Domchek S, Armel S, Isaacs C, Tung N, Sweet K, Ainsworth P, Sun P, Krewski D, Narod S; Hereditary Breast Cancer Clinical Study Group.

Breast. 2010 Dec;19(6):479-83. doi: 10.1016/j.breast.2010.05.009. Epub 2010 Jun 12.

37.

Helpful communications during the diagnostic period: an interpretive description of patient preferences.

Thorne S, Oliffe J, Kim-Sing C, Hislop TG, Stajduhar K, Harris SR, Armstrong EA, Oglov V.

Eur J Cancer Care (Engl). 2010 Nov;19(6):746-54. doi: 10.1111/j.1365-2354.2009.01125.x.

PMID:
19832891
38.

Patient real-time and 12-month retrospective perceptions of difficult communications in the cancer diagnostic period.

Thorne S, Armstrong EA, Harris SR, Hislop TG, Kim-Sing C, Oglov V, Oliffe JL, Stajduhar KI.

Qual Health Res. 2009 Oct;19(10):1383-94. doi: 10.1177/1049732309348382.

PMID:
19805801
39.

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.

Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.

Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16.

40.

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.

Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Natl Cancer Inst. 2008 Oct 1;100(19):1361-7. doi: 10.1093/jnci/djn313. Epub 2008 Sep 23.

41.

Rapid progression of prostate cancer in men with a BRCA2 mutation.

Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P; Hereditary Breast Cancer Study Group, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C.

Br J Cancer. 2008 Jul 22;99(2):371-4. doi: 10.1038/sj.bjc.6604453. Epub 2008 Jun 24.

42.

Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.

Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Cancer Causes Control. 2008 Dec;19(10):1111-9. doi: 10.1007/s10552-008-9175-0. Epub 2008 May 29.

PMID:
18509731
43.

Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.

Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2009 Mar;114(1):127-35. doi: 10.1007/s10549-008-9977-5. Epub 2008 May 16.

44.

Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.

Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S, Poll A, Eisen A, Gilchrist D, Chudley A, Ghadirian P, Maugard C, Lemire EG, Sun P, Narod SA.

Clin Genet. 2008 May;73(5):474-9. doi: 10.1111/j.1399-0004.2008.00988.x. Epub 2008 Mar 12. Review.

PMID:
18341607
45.

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2008 May 1;122(9):2017-22. doi: 10.1002/ijc.23340.

46.

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Clin Oncol. 2008 Mar 1;26(7):1093-7. doi: 10.1200/JCO.2007.12.6078. Epub 2008 Jan 14.

PMID:
18195327
47.

Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.

Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, Eisen A, Howley HE, Simard J; National Hereditary Cancer Task Force.

J Obstet Gynaecol Can. 2007 Jan;29(1):45-60.

PMID:
17346477
48.

Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group, Garber J, Osborne M, Fishman D, McLennan J, McKinnon W, Merajver S, Olsson H, Provencher D, Pasche B, Evans G, Meschino WS, Lemire E, Chudley A, Rayson D, Bellati C.

Breast Cancer Res Treat. 2007 Oct;105(2):221-8. Epub 2007 Jan 24.

PMID:
17245541
49.

Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation.

Metcalfe KA, Ghadirian P, Rosen B, Foulkes W, Kim-Sing C, Eisen A, Ainsworth P, Horsman D, Maugard C, Provencher D, Robideaux A, Gilchrist D, Chudley A, Lemire EG, Armel S, Finch A, Sun P, Narod SA.

Open Med. 2007 Aug 13;1(2):e92-8.

50.

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

JAMA. 2006 Jul 12;296(2):185-92.

Supplemental Content

Loading ...
Support Center